Regeneron’s gene therapy for a profound form of deafness affecting children, DB-OTO, has shown the first signs that it can improve hearing in a clinical trial.
French biotech Sensorion has filed its first regulatory application to start human testing of OTOF-GT, a gene therapy for one of the most common forms of congenital deafne
Eli Lilly has agreed to buy hearing loss gene therapy developer Akouos in a deal that could value the company at around $610 million – if its lead candidate progresses as hoped in the clini
Otonomy has chalked up its second clinical trial failure in the space of a few months, the latest in a mid-stage study of a treatment for hearing loss, and the biotech has now been forced i
Cell therapy specialist Mogrify has struck a deal with Japanese drugmaker Astellas to look at ways to deploy regenerative medicine to treat hearing loss caused by factors such as chronic ex
Owlstone Medical has secured a $5 million equity investment and initial $1.5 million grant funding, committed by the Bill and Melinda Gates Foundation, for development of
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.